Merck Reports Results of Doravirine/Islatravir as Fixed Dose Combination in P-III Trials for the Treatment of HIV-1 Infection

Shots:

The 2 P-III ILLUMINATE SWITCH A & B trials evaluate doravirine/islatravir (100/0.75mg, qd, PO) in a ratio (1:1) in 672 & 641 patients with HIV-1 who are virologically suppressed on different ART regimens or BIC/FTC/TAF
Both the trials met its primary efficacy EPs i.e., the proportion of patients with HIV-1 RNA levels ≥50 copies/mL demonstrated an antiviral efficacy b/w DOR/ISL & ART (ILLUMINATE SWITCH A) and DOR/ISL & BIC/FTC/TAF (ILLUMINATE SWITCH B) @ 48wks., safety & tolerability are consistent with the previously reported P-II studies
Doravirine is approved for HIV-1 in combination with other antiretrovirals as monothx. Pifeltro & Delstrigo. Islatravir is Merck’s NRTTIs inhibitor

Click here to read full press release/ article | Ref: Merck | Image: Spagnola & Associates